March 04, 2013
Pennsylvania has reached a nearly $2 million deal with Healthpoint Ltd. and DFB Pharmaceuticals Inc. to settle allegations that Healthpoint submitted false reimbursement claims to Medicaid for its unapproved skin ulcer ointment Xenaderm, state Attorney General Kathleen G. Kane announced Monday.
February 26, 2013
A Massachusetts federal judge on Monday threw out a decade-old $500 million False Claims Act suit against 24 pharmaceutical companies, including Actavis Mid-Atlantic LLC and Abbott Laboratories Inc., saying the allegations were based on public disclosures rather than the relator's own information.
January 04, 2013
A Massachusetts federal judge on Friday reopened a False Claims Act whistleblower suit against Healthpoint Ltd. over improper billing for Xenaderm skin ointment, giving Indiana officials more time to consider accepting a $48 million deal the federal government reached with other states.
December 20, 2012
Indiana officials on Wednesday asked a Massachusetts federal judge to reopen a False Claims Act whistleblower suit against Healthpoint Ltd. over improper billing for Xenaderm skin ointment, saying they've been unable to reach terms in a matter the federal government recently settled for $48 million.
December 06, 2012
Healthpoint Ltd. and DFB Pharmaceuticals Inc. will pay $48 million as part of a settlement agreement that ended allegations that Healthpoint submitted false claims to Medicare and Medicaid for an unapproved prescription skin ointment, the U.S. Department of Justice said Thursday.
September 28, 2012
Healthpoint Ltd. on Friday agreed to settle a whistleblower's False Claims Act allegations it swindled Medicaid out of at least $90 million by improperly billing for bedsore ointment Xenaderm despite the medication's loss of U.S. Food and Drug Administration approval because of perceived ineffectiveness.
May 18, 2012
Virginia joined the federal government and other states Thursday in accusing Healthpoint Ltd. of costing Medicaid agencies more than $500 million by falsely claiming its bedsore ointment Xenaderm was eligible for reimbursement coverage.
April 26, 2012
Thirteen U.S. states on Wednesday moved to join a whistleblower suit claiming Healthpoint Ltd. caused Medicaid to pay $90 million in claims for bedsore ointment Xenaderm despite the drug's ineligibility for coverage, a month after a judge rejected Healthpoint's bid to toss the suit.
March 26, 2012
A Massachusetts federal judge on Monday tossed Healthpoint Ltd.'s motion to dismiss charges brought by the U.S. Department of Justice claiming it caused Medicaid to pay $90 million in claims for bedsore ointment Xenaderm despite the drug's ineligibility for coverage.
December 06, 2011
KV Pharmaceutical Co. agreed Tuesday to pay $17 million to resolve a former subsidiary's role in a long-running False Claims Act qui tam action alleging it wrongly reported to Medicaid and Medicare programs that two drugs were qualified for coverage under the federal health care systems.